From the Research
Treatment Options for Hypoparathyroidism
The treatment for hypoparathyroidism typically involves calcium supplements and active analogs of vitamin D 1, 2, 3. However, recent studies have explored new therapeutic approaches, including replacement therapy with parathyroid hormone (PTH) 1, 2, 4, 5.
Conventional Treatment
Conventional treatment with calcium and vitamin D can help manage hypocalcemia, but it may not address all aspects of the disease, such as abnormal bone remodeling and reduced quality of life 2, 3. Additionally, long-term complications, including nephrolithiasis, nephrocalcinosis, renal impairment, cataracts, and cerebral calcifications, can occur with conventional treatment 2.
Replacement Therapy with PTH
Replacement therapy with PTH, such as rhPTH (1-84) (Natpara) 2 and PTH (1-34) 4, 5, has been shown to be effective in managing hypoparathyroidism. These therapies can help maintain normal calcium levels, reduce long-term risks associated with conventional therapy, and improve quality of life 2, 4, 5.
New Therapeutic Approaches
New therapeutic approaches, such as palopegteriparatide (TransCon PTH) and eneboparatide, are being developed and tested in clinical trials 4. These therapies aim to provide stable physiological PTH levels for 24 hours/day and have shown promising results in maintaining normocalcemia and improving quality of life 4.
Key Points
- Conventional treatment with calcium and vitamin D is commonly used to manage hypoparathyroidism
- Replacement therapy with PTH is a promising approach for managing hypoparathyroidism
- New therapeutic approaches, such as palopegteriparatide and eneboparatide, are being developed and tested
- Treatment goals include maintaining normal calcium levels, reducing long-term risks, and improving quality of life 1, 2, 3, 4, 5